Associations between HIV, sexually transmitted diseases, and antimicrobial resistance in the era of combination antiretroviral therapy and antibiotics

Abstract

The advancement of combination antiretroviral therapy (cART) has dramatically transformed the management of human immunodeficiency virus (HIV), significantly reducing morbidity and mortality rates. However, the coexistence of sexually transmitted diseases (STDs) and antimicrobial resistance (AMR) presents interconnected challenges that compromise these advances in this era. This review explores the intricate associations between HIV, STDs, and AMR in the framework of extensive cART and antibiotic usage. Published literature on epidemiological data was analyzed to identify the patterns of co-infection and resistance trends, examining how the suppression of HIV influences the prevalence and treatment outcomes of concurrent STDs. Furthermore, the impacts of antibiotic overuse or misuse on the emergence of resistant strains of common bacterial STDs were investigated, particularly focusing on pathogens such as Neisseria gonorrhoeae and Mycoplasma genitalium among HIV-infected individuals. The findings highlight the critical need for integrated surveillance, antimicrobial stewardship, expanded vaccination, and culturally sensitive public health strategies. By enhancing our understanding of these interactions, this review intends to inform alterations in the existing public health policies and to upgrade previously optimized treatment protocols in the near future to improve patient outcomes in the era of cART and antibiotics.

Keywords

HIV / Sexually transmitted disease / Antimicrobial resistance / Combination antiretroviral therapy / Antibiotic era

References

[1] Wu TY, Lin KY, Su LH, et al. Sexually transmitted coinfections among at-risk HIV-positive MSM: Implications for optimal preemptive treatment. Front Med (Lausanne). 2024; 11:1328589. doi: 10.3389/fmed.2024.1328589

[2] Chambers HF,Antibacterial Resistance Leadership Group. Confronting antimicrobial resistance together. Am J Physiol Lung Cell Mol Physiol. 2022; 323(5):L643-L645. doi: 10.1152/ajplung.00327.2022

[3] Wasserheit JN. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis. 1992; 19(2):61-77.

[4] Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004; 2(1):33-42. doi: 10.1038/nrmicro794

[5] Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA. 2013; 110(17):6626-6633. doi: 10.1073/pnas.1304288110

[6] Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol. 2008; 82(8):3952-3970. doi: 10.1128/JVI.02660-07

[7] Looker KJ, Elmes JAR, Gottlieb SL, et al. Effect of HSV-2 infection on subsequent HIV acquisition: An updated systematic review and meta-analysis. Lancet Infect Dis. 2017; 17(12):1303-1316. doi: 10.1016/S1473-3099(17)30405-X

[8] Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study. Lancet. 2019; 393(10189):2428-2438. doi: 10.1016/S0140-6736(19)30418-0

[9] Cunningham S, Kendall TD. Risk behaviours among internet-facilitated sex workers: Evidence from two new datasets. Sex Transm Infect. 2010; 86(Suppl 3):iii100-iii105. doi: 10.1136/sti.2010.044875

[10] Hanum N, Cambiano V, Sewell J, et al.Trends in HIV incidence between2013-2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort study. PLoS Med. 2021; 18(6):e1003677. doi: 10.1371/journal.pmed.1003677

[11] Pollock L, Levison J. 2023 updated guidelines on infant feeding and HIV in the United States: What are they and why have recommendations changed. Top Antivir Med. 2023; 31(5):576-586.

[12] Usama Irshad, Heba Mahdy, Tiffany Tonismae. HIV in Pregnancy; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/nbk558972 [Last accessed on 2025 Aug 08].

[13] De La Torre Tarazona E, Moraga E, Vaquer R, et al. Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size. Sci Rep. 2025; 15(1):25306. doi: 10.1038/s41598-025-09474-1

[14] Bai R, Lv S, Wu H, Dai L. Insights into the HIV-1 latent reservoir and strategies to cure HIV-1 infection. Dis Markers. 2022; 2022:6952286. doi: 10.1155/2022/6952286

[15] Massanella M, Ignacio RAB, Lama JR, et al. Long-term effects of early antiretroviral initiation on HIV reservoir markers: A longitudinal analysis of the MERLIN clinical study. Lancet Microbe. 2021; 2(5):e198-e209. doi: 10.1016/s2666-5247(21)00010-0

[16] Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: Undetectable equals untransmittable. JAMA. 2019; 321(5):451. doi: 10.1001/jama.2018.21167

[17] Pillay R, Naidoo P, Mkhize-Kwitshana ZL. Herpes simplex virus type 2 in Sub-Saharan Africa and the potential impact of helminth immune modulation. Front Cell Infect Microbiol. 2024; 14:1471411. doi: 10.3389/fcimb.2024.1471411

[18] Bamberger DM.Trends in sexually transmitted infections. Mo Med. 2020; 117(4):324-327.

[19] Elendu C, Amaechi DC, Elendu ID, et al. Global perspectives on the burden of sexually transmitted diseases: A narrative review. Medicine. 2024; 103(20):e38199. doi: 10.1097/MD.0000000000038199

[20] Rowley J, Vander Hoorn S, Korenromp E, et al.Chlamydia, gonorrhoea, trichomoniasis and syphilis: Global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019; 97(8):548-562. doi: 10.2471/BLT.18.228486

[21] Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: The biologic basis for epidemiologic synergy. J Intern AIDS Soc. 2019; 22(S6):e25355. doi: 10.1002/jia2.25355

[22] Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med. 2011; 365(6):493-505. doi: 10.1056/nejmoa1105243

[23] Lodi S, Phillips A, Fidler S, et al. Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. PLoS One. 2013; 8(9):e75608. doi: 10.1371/journal.pone.0075608

[24] Patel P, Rose CE, Kjetland EF, et al. Association of schistosomiasis and HIV infections: A systematic review and meta-analysis. Int J Infect Dis. 2021; 102:544-553. doi: 10.1016/j.ijid.2020.10.088

[25] Benslama L. Oral and maxillofacial manifestations of human immunodefficiency virus infection. J Stomatol Oral Maxillofac Surg. 2022; 123(6):622-633. doi: 10.1016/j.jormas.2022.05.003

[26] Slaven EM. Human immunodeficiency virus infection. In: Emergency Medicine. Amsterdam: Elsevier; 2013. p. 1475-1482.e1. doi: 10.1016/B978-1-4377-3548-2.00175-0

[27] Weichseldorfer M, Reitz M, Latinovic OS. Past HIV-1 medications and the current status of combined antiretroviral therapy options for HIV-1 patients. Pharmaceutics. 2021; 13(11):1798. doi: 10.3390/pharmaceutics13111798

[28] Kaplan JE, Dominguez K, Jobarteh K, Spira TJ. Postexposure prophylaxis against human immunodeficiency virus (HIV): New guidelines from the WHO: A perspective. Clin Infect Dis. 2015; 60(Suppl 3):S196-S199. doi: 10.1093/cid/civ087

[29] Lal RB, Chakrabarti S, Yang C. Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy and vaccine development. Indian J Med Res. 2005; 121(4):287-314.

[30] Sherman MP, De Noronha CMC, Williams SA, Greene WC. Insights into the biology of HIV-1 viral protein R. DNA Cell Biol. 2002; 21(9):679-688. doi: 10.1089/104454902760330228

[31] Lu YL, Spearman P, Ratner L. Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J Virol. 1993; 67(11):6542-6550. doi: 10.1128/jvi.67.11.6542-6550.1993

[32] Fouchier RAM, Meyer BE, Simon JHM, et al. Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol. 1998; 72(7):6004-6013. doi: 10.1128/JVI.72.7.6004-6013.1998

[33] Mahalingam S, Ayyavoo V, Patel M, Kieber-Emmons T, Weiner DB. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol. 1997; 71(9):6339-6347. doi: 10.1128/jvi.71.9.6339-6347.1997

[34] Greenwood EJD, Williamson JC, Sienkiewicz A, Naamati A, Matheson NJ, Lehner PJ. Promiscuous targeting of cellular proteins by Vpr drives systems-level proteomic remodeling in HIV-1 infection. Cell Rep. 2019; 27(5):1579-1596.e7. doi: 10.1016/j.celrep.2019.04.025

[35] Chehelgerdi M, Chehelgerdi M, Khorramian- Ghahfarokhi M, et al. Comprehensive review of CRISPR-based gene editing: Mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024; 23(1):9. doi: 10.1186/s12943-023-01925-5

[36] Ewongwo A, Sahor AF, Ngwa W, Nwachukwu C. A guide to global access to HPV vaccination to all women in low- and middle-income countries; a minireview of innovation and equity. Front Oncol. 2024; 14:1380663. doi: 10.3389/fonc.2024.1380663

[37] Nema V, Jadhav S. Significance of upcoming technologies and their potential applications in understanding microbial diversity. In: Microbial Diversity in the Genomic Era. Amsterdam: Elsevier; 2024. p. 697-712. doi: 10.1016/B978-0-443-13320-6.00003-2

[38] Kellokoski J, Syrjänen S, Syrjänen K, Yliskoski M. Oral mucosal changes in women with genital HPV infection. J Oral Pathol Med. 1990; 19(3):142-148. doi: 10.1111/j.1600-0714.1990.tb00813.x

[39] Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015; 64(RR-03):1-137.

[40] Owusu-Edusei K, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013; 40(3):197-201. doi: 10.1097/olq.0b013e318285c6d2

[41] Satterwhite CL, Torrone E, Meites E, et al.Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis. 2013; 40(3):187-193. doi: 10.1097/olq.0b013e318286bb53

[42] Chavula MP, Zulu JM, Hurtig AK. Factors influencing the integration of comprehensive sexuality education into educational systems in low- and middle-income countries: A systematic review. Reprod Health. 2022; 19(1):196. doi: 10.1186/s12978-022-01504-9

[43] Rojas P, Huang H, Li T, et al. Sociocultural determinants of risky sexual behaviors among adult latinas: A longitudinal study of a community-based sample. Int J Environ Res Public Health. 2016; 13(11):1164. doi: 10.3390/ijerph13111164

[44] Kabiru CW, Munthali A, Sawadogo N, et al. Effectiveness of conditional cash transfers, subsidized child care and life skills training on adolescent mothers’ schooling, sexual and reproductive health, and mental health outcomes in Burkina Faso and Malawi: The PROMOTE Project pilot randomized controlled trial protocol. Reprod Health. 2023; 20(1):166. doi: 10.1186/s12978-023-01706-9

[45] Malhotra A, Elnakib S. 20 Years of the evidence base on what works to prevent child marriage: A systematic review. J Adolescent Health. 2021; 68(5):847-862. doi: 10.1016/j.jadohealth.2020.11.017

[46] Cates W Jr. Acquired immunodeficiency syndrome, sexually transmitted diseases, and epidemiology. Past lessons, present knowledge, and future opportunities. Am J Epidemiol. 1990; 131(5):749-758. doi: 10.1093/oxfordjournals.aje.a115564

[47] Stamm WE, Guinan ME, Johnson C, Starcher T, Holmes KK, McCormack WM. Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis. N Engl J Med. 1984; 310(9):545-549. doi: 10.1056/nejm198403013100901

[48] Sahoo R, Jadhav S, Nema V. Journey of technological advancements in the detection of antimicrobial resistance. J Formos Med Assoc. 2024; 123(4):430-441. doi: 10.1016/j.jfma.2023.08.008

[49] Fox KK, Whittington WL, Levine WC, Moran JS, Zaidi AA, Nakashima AK. Gonorrhea in the United States, 1981-1996. Demographic and geographic trends. Sex Transm Dis. 1998; 25(7):386-393. doi: 10.1097/00007435-199808000-00011

[50] Centers for Disease Control and Prevention (CDC). Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012; 61(31):590-594.

[51] Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Eurosurveillance. 2018; 23(27):1800323. doi: 10.2807/1560-7917.es.2018.23.27.1800323

[52] Wi T, Lahra MM, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med. 2017; 14(7):e1002344. doi: 10.1371/journal.pmed.1002344

[53] Zhang Y, Qiu K, Ren J, Zhao Y, Cheng P. Roles of human papillomavirus in cancers: Oncogenic mechanisms and clinical use. Signal Transduct Target Ther. 2025; 10(1):44. doi: 10.1038/s41392-024-02083-w

[54] Kreisel KM, Spicknall IH, Gargano JW, et al.Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2018. Sex Transm Dis. 2021; 48(4):208-214. doi: 10.1097/OLQ.0000000000001355

[55] Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis. 2014; 209(3):325-333. doi: 10.1093/infdis/jit458

[56] Siracusano S, Silvestri T, Casotto D. Sexually transmitted diseases: Epidemiological and clinical aspects in adults. Urologia. 2014; 81(4):200-208. doi: 10.5301/uro.5000101

[57] Centers for Disease Control and Prevention, Workowski KA, Berman SM.Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006; 55(RR-11):1-94.

[58] Scoular A. Using the evidence base on genital herpes: Optimising the use of diagnostic tests and information provision. Sex Transm Infect. 2002; 78(3):160-165. doi: 10.1136/sti.78.3.160

[59] Scoular A. Polymerase chain reaction for diagnosis of genital herpes in a genitourinary medicine clinic. Sex Transm Infect. 2002; 78(1):21-25. doi: 10.1136/sti.78.1.21

[60] DeJesus E, Wald A, Warren T, et al. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis. 2003; 188(7):1009-1016. doi: 10.1086/378416

[61] Sawleshwarkar S, Dwyer DE. Antivirals for herpes simplex viruses: BMJ. 2015;351:h3350. doi: 10.1136/bmj.h3350

[62] Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats. P T. 2015; 40(4):277-283.

[63] Laws M, Shaaban A, Rahman KM. Antibiotic resistance breakers: Current approaches and future directions. FEMS Microbiol Rev. 2019; 43(5):490-516. doi: 10.1093/femsre/fuz014

[64] Lechner I, Freivogel C, Stärk KDC, Visschers VHM. Exposure pathways to antimicrobial resistance at the human-animal interface-a qualitative comparison of swiss expert and consumer opinions. Front Public Health. 2020; 8:345. doi: 10.3389/fpubh.2020.00345

[65] D’Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature. 2011; 477(7365):457-461. doi: 10.1038/nature10388

[66] Spink WW, Ferris V. Penicillin-resistant staphylococci: Mechanisms involved in the development of resistance. J Clin Invest. 1947; 26(3):379-393. doi: 10.1172/jci101820

[67] Davies JE, Behroozian S. An ancient solution to a modern problem. Mol Microbiol. 2020; 113(3):546-549. doi: 10.1111/mmi.14481

[68] Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: A population-level modelling analysis. Lancet Infect Dis. 2019; 19(1):56-66. doi: 10.1016/S1473-3099(18)30605-4

[69] Lim C, Takahashi E, Hongsuwan M, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. eLife. 2016; 5:e18082. doi: 10.7554/eLife.18082

[70] Gandra S, Tseng KK, Arora A, et al. The mortality burden of multidrug-resistant pathogens in India: A retrospective, observational study. Clin Infect Dis. 2019; 69(4):563-570. doi: 10.1093/cid/ciy955

[71] O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. Gov United Kingdom. 2016; 1(1):1-84.

[72] Workowski KA, Bachmann LH, Chan PA, et al.Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021; 70(4):1-187. doi: 10.15585/mmwr.rr7004a1

[73] Irenge LM, Ambroise J, Bearzatto B, Durant JF, Bonjean M, Gala JL. Genomic characterization of multidrug-resistant extended spectrum β-lactamase-producing Klebsiella pneumoniae from clinical samples of a tertiary hospital in South Kivu Province, Eastern democratic Republic of Congo. Microorganisms. 2023; 11(2):525. doi: 10.3390/microorganisms11020525

[74] Piselli C, Benz R. Fosmidomycin transport through the phosphate-specific porins OprO and OprP of Pseudomonas aeruginosa. Mol Microbiol. 2021; 116(1):97-108. doi: 10.1111/mmi.14693

[75] Leus IV, Adamiak J, Trinh AN, et al. Inactivation of AdeABC and AdeIJK efflux pumps elicits specific nonoverlapping transcriptional and phenotypic responses in Acinetobacter baumannii. Mol Microbiol. 2020; 114(6):1049-1065. doi: 10.1111/mmi.14594

[76] Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis. 2008; 197(8):1079-1081. doi: 10.1086/533452

[77] Bertolla F, Kay E, Simonet P. Potential dissemination of antibiotic resistance genes from transgenic plants to microorganisms. Infect Control Hosp Epidemiol. 2000; 21(6):390-393. doi: 10.1086/501779

[78] Dantas G, Sommer MOA, Oluwasegun RD, Church GM.Bacteria subsisting on antibiotics. Science. 2008; 320(5872):100-103. doi: 10.1126/science.1155157

[79] Nikaido H.Multidrug resistance in Bacteria. Annu Rev Biochem. 2009; 78(1):119-146. doi: 10.1146/annurev.biochem.78.082907.145923

[80] Bryan LE, Kwan S. Aminoglycoside-resistant mutants of Pseudomonas aeruginosa deficient in cytochrome d, nitrite reductase, and aerobic transport. Antimicrob Agents Chemother. 1981; 19(6):958-964. doi: 10.1128/aac.19.6.958

[81] Ghasemian A, Salimian Rizi K, Rajabi Vardanjani H, Nojoomi F. Prevalence of clinically isolated metallo-beta-lactamase-producing Pseudomonas aeruginosa, coding genes, and possible risk factors in Iran. Iran J Pathol. 2018; 13(1):1-9.

[82] Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence-implications for human health and treatment perspectives. EMBO Rep. 2020; 21(12):e51034. doi: 10.15252/embr.202051034

[83] Fernández-Billón M, Llambías-Cabot AE, Jordana-Lluch E, Oliver A, Macià MD. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa biofilms. Biofilm. 2023; 5:100129. doi: 10.1016/j.bioflm.2023.100129

[84] Du X, Zhang L, Luo H, et al. Factors associated with risk sexual behaviours of HIV/STDs infection among university students in Henan, China: A cross-sectional study. Reprod Health. 2021; 18(1):172. doi: 10.1186/s12978-021-01219-3

[85] Luther A, Urfer M, Zahn M, et al. Chimeric peptidomimetic antibiotics against Gram-negative bacteria. Nature. 2019; 576(7787):452-458. doi: 10.1038/s41586-019-1665-6

[86] Sader HS, Rhomberg PR, Duncan LR, Locher HH, Dale GE, Flamm RK. Antimicrobial activity of POL 7306 tested against clinical isolates of Gram-negative bacteria collected worldwide. J Antimicrob Chemother. 2020; 75(6):1518-1524. doi: 10.1093/jac/dkaa020

[87] Mann A, Nehra K, Rana JS, Dahiya T. Antibiotic resistance in agriculture: Perspectives on upcoming strategies to overcome upsurge in resistance. Curr Res Microb Sci. 2021; 2:100030. doi: 10.1016/j.crmicr.2021.100030

[88] Enshaie E, Nigam S, Patel S, Rai V. Livestock antibiotics use and antimicrobial resistance. Antibiotics (Basel). 2025; 14(6):621. doi: 10.3390/antibiotics14060621

[89] Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: Treatment outcomes in 6 countries. JAMA. 2000; 283(19):2537. doi: 10.1001/jama.283.19.2537

[90] Genina N, Boetker JP, Colombo S, Harmankaya N, Rantanen J, Bohr A. Anti-tuberculosis drug combination for controlled oral delivery using 3D printed compartmental dosage forms: From drug product design to in vivo testing. J Control Release. 2017; 268:40-48. doi: 10.1016/j.jconrel.2017.10.003

[91] Wienkers LC. Leveraging ADME/PK information to enable knowledge-driven decisions in drug discovery and development. In: Overcoming Obstacles in Drug Discovery and Development. Amsterdam: Elsevier; 2023. p. 9-24. doi: 10.1016/B978-0-12-817134-9.00021-0

[92] Qiu Y, Zhang Y, Deng Y, Liu S, Zhang W. A comprehensive review of computational methods for drug-drug interaction detection. IEEE/ACM Trans Comput Biol and Bioinf. 2022; 19(4):1968-1985. doi: 10.1109/tcbb.2021.3081268

[93] Aronson JK, Green AR. Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. Brit J Clin Pharma. 2020; 86(11):2114-2122. doi: 10.1111/bcp.14327

[94] Palleria C, Roberti R, Iannone LF, et al. Clinically relevant drug interactions between statins and antidepressants. J Clin Pharm Ther. 2020; 45(2):227-239. doi: 10.1111/jcpt.13058

[95] Zheng L, Jin HB, Guan YY, Yang J. Pharmacovigilance of cutaneous adverse drug reactions in associations with drugs and medical conditions: A retrospective study of hospitalized patients. BMC Pharmacol Toxicol. 2022; 23(1):62. doi: 10.1186/s40360-022-00603-4

[96] Seña AC, Bachmann L, Johnston C, et al. Optimising treatments for sexually transmitted infections: Surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. Lancet Infect Dis. 2020; 20(8):e181-e191. doi: 10.1016/S1473-3099(20)30171-7

[97] Zhang Y, Guy R, Camara H, et al. Barriers and facilitators to HIV and syphilis rapid diagnostic testing in antenatal care settings in low-income and middle-income countries: A systematic review. BMJ Glob Health. 2022; 7(11):e009408. doi: 10.1136/bmjgh-2022-009408